ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of “Moderate Buy” from Brokerages

by · The Cerbat Gem

ProQR Therapeutics N.V. (NASDAQ:PRQR – Get Free Report) has received an average rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.3333.

PRQR has been the topic of a number of research analyst reports. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Wall Street Zen cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. JonesTrading lowered their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Finally, Chardan Capital cut their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th.

View Our Latest Stock Analysis on ProQR Therapeutics

Insiders Place Their Bets

In other ProQR Therapeutics news, CEO Boer Daniel Anton De acquired 150,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was acquired at an average cost of $1.74 per share, with a total value of $261,000.00. Following the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. This represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bart Filius bought 150,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were acquired at an average price of $1.54 per share, for a total transaction of $231,000.00. Following the completion of the transaction, the director directly owned 150,000 shares in the company, valued at approximately $231,000. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 450,000 shares of company stock valued at $730,500 over the last three months. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc boosted its holdings in shares of ProQR Therapeutics by 28.4% in the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock worth $5,960,000 after purchasing an additional 651,853 shares during the period. Privium Fund Management B.V. raised its holdings in ProQR Therapeutics by 7.2% during the 4th quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after buying an additional 359,475 shares during the period. Moody Lynn & Lieberson LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at $50,000. Boothbay Fund Management LLC lifted its position in ProQR Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 248,290 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 24,160 shares during the last quarter. Finally, Palo Alto Investors LP bought a new stake in ProQR Therapeutics in the third quarter worth $402,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR opened at $1.67 on Friday. The company has a market cap of $175.95 million, a P/E ratio of -3.34 and a beta of 0.04. ProQR Therapeutics has a 52-week low of $1.33 and a 52-week high of $3.10. The firm’s fifty day moving average is $1.63 and its two-hundred day moving average is $1.66.

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, analysts forecast that ProQR Therapeutics will post -0.52 EPS for the current fiscal year.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

See Also